Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.

Mullins SR, Vasilakos JP, Deschler K, Grigsby I, Gillis P, John J, Elder MJ, Swales J, Timosenko E, Cooper Z, Dovedi SJ, Leishman AJ, Luheshi N, Elvecrog J, Tilahun A, Goodwin R, Herbst R, Tomai MA, Wilkinson RW.

J Immunother Cancer. 2019 Sep 11;7(1):244. doi: 10.1186/s40425-019-0724-8.

2.

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity.

Nelson N, Lopez-Pelaez M, Palazon A, Poon E, De La Roche M, Barry S, Valge-Archer V, Wilkinson RW, Dovedi SJ, Smith PD.

Oncoimmunology. 2019 Apr 26;8(8):1599635. doi: 10.1080/2162402X.2019.1599635. eCollection 2019.

3.

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.

Kosinsky Y, Dovedi SJ, Peskov K, Voronova V, Chu L, Tomkinson H, Al-Huniti N, Stanski DR, Helmlinger G.

J Immunother Cancer. 2018 Feb 27;6(1):17. doi: 10.1186/s40425-018-0327-9.

4.

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.

Poon E, Mullins S, Watkins A, Williams GS, Koopmann JO, Di Genova G, Cumberbatch M, Veldman-Jones M, Grosskurth SE, Sah V, Schuller A, Reimer C, Dovedi SJ, Smith PD, Stewart R, Wilkinson RW.

J Immunother Cancer. 2017 Aug 15;5(1):63. doi: 10.1186/s40425-017-0268-8.

5.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Oct;31(10):2278. doi: 10.1038/leu.2017.218. Epub 2017 Jul 28.

PMID:
28751765
6.

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.

Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, Robins HS, Wilkinson RW, Honeychurch J, Illidge TM.

Clin Cancer Res. 2017 Sep 15;23(18):5514-5526. doi: 10.1158/1078-0432.CCR-16-1673. Epub 2017 May 22.

7.

Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.

Oguejiofor K, Galletta-Williams H, Dovedi SJ, Roberts DL, Stern PL, West CM.

Oncotarget. 2017 Feb 28;8(9):14416-14427. doi: 10.18632/oncotarget.14796.

8.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.

Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt DM, Ahdesmaki MJ, Leyland R, Mullins S, Pacelli L, Marcus D, Anderton J, Watkins A, Coates Ulrichsen J, Brohawn P, Higgs BW, McCourt M, Jones H, Harper JA, Morrow M, Valge-Archer V, Stewart R, Dovedi SJ, Wilkinson RW.

Cancer Immunol Res. 2017 Jan;5(1):29-41. doi: 10.1158/2326-6066.CIR-16-0114. Epub 2016 Dec 6.

9.

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, Fagnano E, Klein C, Honeychurch J, Illidge TM.

Leukemia. 2017 Jul;31(7):1611-1621. doi: 10.1038/leu.2016.352. Epub 2017 Nov 28. Erratum in: Leukemia. 2017 Jul 28;:.

10.

Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells.

Dovedi SJ, Lipowska-Bhalla G, Beers SA, Cheadle EJ, Mu L, Glennie MJ, Illidge TM, Honeychurch J.

Cancer Immunol Res. 2016 Jul;4(7):621-630. doi: 10.1158/2326-6066.CIR-15-0253. Epub 2016 May 30.

11.

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.

Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM.

Oncotarget. 2016 Mar 29;7(13):17035-46. doi: 10.18632/oncotarget.7928.

12.

Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer.

Joseph N, Dovedi SJ, Thompson C, Lyons J, Kennedy J, Elliott T, West CM, Choudhury A.

Ann Oncol. 2016 Feb;27(2):294-9. doi: 10.1093/annonc/mdv546. Epub 2015 Nov 16.

PMID:
26578732
14.

TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.

Koga-Yamakawa E, Murata M, Dovedi SJ, Wilkinson RW, Ota Y, Umehara H, Sugaru E, Hirose Y, Harada H, Jewsbury PJ, Yamamoto S, Robinson DT, Li CJ.

Cancer Immunol Immunother. 2015 Oct;64(10):1229-39. doi: 10.1007/s00262-015-1730-4. Epub 2015 Jun 20.

PMID:
26091797
15.

Immuno-regulatory antibodies for the treatment of cancer.

Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM.

Expert Opin Biol Ther. 2015 Jun;15(6):787-801. doi: 10.1517/14712598.2015.1036737. Epub 2015 Apr 16. Review.

PMID:
25882106
16.

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM.

Cancer Res. 2014 Oct 1;74(19):5458-68. doi: 10.1158/0008-5472.CAN-14-1258.

17.

A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.

Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ.

Int J Cancer. 2014 Aug 15;135(4):820-9. doi: 10.1002/ijc.28711. Epub 2014 Jan 17.

18.

The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.

Cheadle EJ, Sidon L, Dovedi SJ, Melis MH, Alduaij W, Illidge TM, Honeychurch J.

Br J Haematol. 2013 Sep;162(6):842-5. doi: 10.1111/bjh.12427. Epub 2013 Jun 18. No abstract available.

PMID:
23772929
19.

Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response.

Melis MH, Simpson KL, Dovedi SJ, Welman A, MacFarlane M, Dive C, Honeychurch J, Illidge TM.

Cell Death Differ. 2013 May;20(5):765-73. doi: 10.1038/cdd.2013.8. Epub 2013 Feb 15.

20.

Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations.

Honeychurch J, Melis MH, Dovedi SJ, Mu L, Illidge TM.

Leuk Lymphoma. 2013 Sep;54(9):2008-15. doi: 10.3109/10428194.2013.769219. Epub 2013 Feb 18.

PMID:
23339450
21.

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.

Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, Honeychurch J, Illidge TM.

Blood. 2013 Jan 10;121(2):251-9. doi: 10.1182/blood-2012-05-432393. Epub 2012 Oct 18.

PMID:
23086756
22.

Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer.

Koga-Yamakawa E, Dovedi SJ, Murata M, Matsui H, Leishman AJ, Bell J, Ferguson D, Heaton SP, Oki T, Tomizawa H, Bahl A, Takaku H, Wilkinson RW, Harada H.

Int J Cancer. 2013 Feb 1;132(3):580-90. doi: 10.1002/ijc.27691. Epub 2012 Jul 11.

23.

T regulatory cells in cancer: recent advances and therapeutic potential.

Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE.

Expert Opin Biol Ther. 2010 Nov;10(11):1573-86. doi: 10.1517/14712598.2010.529126. Review.

PMID:
20955112
24.

Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.

Khan AR, Dovedi SJ, Wilkinson RW, Pritchard DI.

Int Rev Immunol. 2010 Oct;29(5):461-84. doi: 10.3109/08830185.2010.508854. Review.

PMID:
20839911
25.

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE.

J Immunol. 2010 Feb 15;184(4):1885-96. doi: 10.4049/jimmunol.0901440. Epub 2010 Jan 20.

26.

Emerging targeted therapies for bladder cancer: a disease waiting for a drug.

Dovedi SJ, Davies BR.

Cancer Metastasis Rev. 2009 Dec;28(3-4):355-67. doi: 10.1007/s10555-009-9192-9. Review.

PMID:
19997963
27.

Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.

Dovedi SJ, Kirby JA, Davies BR, Leung H, Kelly JD.

Eur Urol. 2008 Sep;54(3):621-30. doi: 10.1016/j.eururo.2008.01.013. Epub 2008 Jan 15.

PMID:
18222600
28.

Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.

Dovedi SJ, Kirby JA, Atkins H, Davies BR, Kelly JD.

J Urol. 2005 Jul;174(1):332-7; discussion 337.

PMID:
15947685

Supplemental Content

Loading ...
Support Center